Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease

Overview

Journal Front Neurosci

Date 2018 May 10

PMID 29740272

Citations 9

Authors

Isabelle L Sumner

Ross A Edwards

Ayodeji A Asuni

Jessica L Teeling

Affiliations

Soon will be listed here.

Abstract

There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease modifying treatment is available. AD is characterized by deposits of Amyloid-β (Aβ), neurofibrillary tangles, and neuroinflammation, and several drug discovery programmes studies have focussed on Aβ as therapeutic target. Active immunization and passive immunization against Aβ leads to the clearance of deposits in humans and transgenic mice expressing human Aβ but have failed to improve memory loss. This review will discuss the possible explanations for the lack of efficacy of Aβ immunotherapy, including the role of a pro-inflammatory response and subsequent vascular side effects, the binding site of therapeutic antibodies and the timing of the treatment. We further discuss how antibodies can be engineered for improved efficacy.

Citing Articles

Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects.

Loeffler D J Alzheimers Dis Rep. 2023; 7(1):873-899.

PMID: 37662616 PMC: 10473157. DOI: 10.3233/ADR-230025.

Review of Alzheimer's disease drugs and their relationship with neuron-glia interaction.

Ajenikoko M, Ajagbe A, Onigbinde O, Okesina A, Tijani A IBRO Neurosci Rep. 2023; 14:64-76.

PMID: 36593897 PMC: 9803919. DOI: 10.1016/j.ibneur.2022.11.005.

Engineering antibody and protein therapeutics to cross the blood-brain barrier.

Zhao P, Zhang N, An Z Antib Ther. 2022; 5(4):311-331.

PMID: 36540309 PMC: 9759110. DOI: 10.1093/abt/tbac028.

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates.

Ramakrishnan V, Friedrich C, Witt C, Sheehan R, Pryor M, Atwal J CPT Pharmacometrics Syst Pharmacol. 2022; 12(1):62-73.

PMID: 36281062 PMC: 9835125. DOI: 10.1002/psp4.12876.

The Immune System as a Therapeutic Target for Alzheimer's Disease.

Zieneldien T, Kim J, Sawmiller D, Cao C Life (Basel). 2022; 12(9).

PMID: 36143476 PMC: 9506058. DOI: 10.3390/life12091440.

References

Carvalho D, St Louis E, Knopman D, Boeve B, Lowe V, Roberts R . Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurol. 2018; 75(6):672-680. PMC: 5885188. DOI: 10.1001/jamaneurol.2018.0049. View

Hu N, Klyubin I, Anwyl R, Anwy R, Rowan M . GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci U S A. 2009; 106(48):20504-9. PMC: 2787128. DOI: 10.1073/pnas.0908083106. View

Benitez B, Jin S, Guerreiro R, Graham R, Lord J, Harold D . Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging. 2014; 35(6):1510.e19-26. PMC: 3961557. DOI: 10.1016/j.neurobiolaging.2013.12.010. View

Sattlecker M, Khondoker M, Proitsi P, Williams S, Soininen H, Kloszewska I . Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. J Alzheimers Dis. 2015; 49(4):1105-14. DOI: 10.3233/JAD-140669. View

Bouter Y, Noguerola J, Tucholla P, Crespi G, Parker M, Wiltfang J . Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathol. 2015; 130(5):713-29. DOI: 10.1007/s00401-015-1489-x. View

Kessels H, Nabavi S, Malinow R . Metabotropic NMDA receptor function is required for β-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A. 2013; 110(10):4033-8. PMC: 3593880. DOI: 10.1073/pnas.1219605110. View

Weitz T, Town T . Amyloid Cascade into Clarity. Immunity. 2016; 45(4):717-718. DOI: 10.1016/j.immuni.2016.10.006. View

Strittmatter W, Weisgraber K, Huang D, Dong L, Salvesen G, Pericak-Vance M . Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90(17):8098-102. PMC: 47295. DOI: 10.1073/pnas.90.17.8098. View

Cabrera E, Mathews P, Mezhericher E, Beach T, Deng J, Neubert T . Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(1):208-225. PMC: 5875988. DOI: 10.1016/j.bbadis.2017.07.005. View

10.

Ide M, Harris M, Stevens A, Sussams R, Hopkins V, Culliford D . Periodontitis and Cognitive Decline in Alzheimer's Disease. PLoS One. 2016; 11(3):e0151081. PMC: 4786266. DOI: 10.1371/journal.pone.0151081. View

11.

Weekman E, Sudduth T, Caverly C, Kopper T, Phillips O, Powell D . Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity. J Neurosci. 2016; 36(38):9896-907. PMC: 5030351. DOI: 10.1523/JNEUROSCI.1762-16.2016. View

12.

Pardridge W . Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies. Expert Opin Biol Ther. 2016; 16(12):1455-1468. DOI: 10.1080/14712598.2016.1230195. View

13.

Sumbria R, Hui E, Lu J, Boado R, Pardridge W . Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol Pharm. 2013; 10(9):3507-13. DOI: 10.1021/mp400348n. View

14.

Jawhar S, Wirths O, Bayer T . Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease. J Biol Chem. 2011; 286(45):38825-32. PMC: 3234707. DOI: 10.1074/jbc.R111.288308. View

15.

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

16.

Kalback W, Watson M, Kokjohn T, Kuo Y, Weiss N, Luehrs D . APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 2002; 41(3):922-8. DOI: 10.1021/bi015685+. View

17.

Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris C . Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol. 2006; 32(2):103-18. DOI: 10.1111/j.1365-2990.2006.00696.x. View

18.

Portelius E, Bogdanovic N, Gustavsson M, Volkmann I, Brinkmalm G, Zetterberg H . Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 2010; 120(2):185-93. PMC: 3568930. DOI: 10.1007/s00401-010-0690-1. View

19.

Cynis H, Frost J, Crehan H, Lemere C . Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges. Mol Neurodegener. 2016; 11(1):48. PMC: 4929720. DOI: 10.1186/s13024-016-0115-2. View

20.

Perl D . Neuropathology of Alzheimer's disease. Mt Sinai J Med. 2010; 77(1):32-42. PMC: 2918894. DOI: 10.1002/msj.20157. View